Table 3.
Mixed effects logistic regression for the absence of rhythmic components in blood pressure among AASK cohort participants.
| Covariate | Odds ratio | 95% CI lower | 95% CI upper | P-value |
|---|---|---|---|---|
| Age < 45 | Reference | |||
| Age from 45 to <65 | 1.5 | 0.61 | 3.7 | 0.379 |
| Age 65+ | 2.23 | 0.88 | 5.64 | 0.091 |
| BMI < 25 | Reference | |||
| BMI 25 to <30 | 1.09 | 0.62 | 1.91 | 0.757 |
| BMI ≥ 30 | 1.84 | 1.05 | 3.22 | 0.033 |
| eGFR >60 ml/min/1.73 m2 | Reference | |||
| eGFR: 30 to <60 ml/min/1.73 m2 | 0.38 | 0.12 | 1.21 | 0.101 |
| eGFR < 30 ml/min/1.73 m2 | 0.43 | 0.13 | 1.41 | 0.165 |
| Proteinuria (PCR < 150 mg/g) | Reference | |||
| Proteinuria (PCR: 150–500 mg/g) | 1.43 | 0.85 | 2.4 | 0.176 |
| Proteinuria (PCR > 500 mg/g) | 1.65 | 0.98 | 2.78 | 0.062 |
| Controlled BP | Reference | |||
| Uncontrolled BP (Mean 24 h BP ≥ 125/75 mmHg) | 1.04 | 0.66 | 1.65 | 0.862 |
| Male sex | Reference | |||
| Female sex | 1.18 | 0.77 | 1.79 | 0.448 |
| Non-diabetic | Reference | |||
| Diabetic | 0.63 | 0.35 | 1.18 | 0.119 |
| Prior CVD: No | Reference | |||
| Prior CVD: Yes | 0.95 | 0.52 | 1.43 | 0.792 |
| Drug randomization group: ACE I | Reference | |||
| Drug randomization group: Beta blocker | 1.08 | 0.7 | 1.68 | 0.716 |
| Drug randomization group: CCB | 0.93 | 0.52 | 1.67 | 0.815 |
| BP target randomization group: lower target (MAP < 92) | Reference | |||
| BP target randomization group: usual target (MAP 102–107) | 1.22 | 0.82 | 1.81 | 0.328 |
| Time from initial ABPM (years) | 0.91 | 0.82 | 1.01 | 0.076 |
All variables in the table were included as covariates in the model.
eGFR estimated glomerular filtration rate by the 2021 CKD-EPI equation, PCR urine protein to creatinine ratio, BP blood pressure, ACE I angiotensin converting enzyme inhibitor, CCB calcium channel blocker.